Corimmun GmbH

Venture investors have historically favored early-stage deals, at least in medtech investing, willingly embracing greater technology or market risk for the larger returns that come with being first in

The US FDA Center for Drug Evaluation and Research’s novel approvals class of 2022 is notable for the absence of very fast reviews – approvals that come within six months of submission, or at least tw

Bristol Myers Squibb Company ’s Sotyku and Mallinckrodt plc ’s Terlivez provided two different kinds of examples that the late summer doldrums that had afflicted the novel approvals at the US FDA are

Hematology and orphan or untreated diseases emerged as themes for the US Food and Drug Administration’s mid-June approvals and recent applications. Alnylam Pharmaceuticals Inc. demonstrated the grow